Skip to content
AnalystLens

Exelixis Quarterly Report for Q1 Ended Apr 4, 2025

Filing Date
Filed May 13, 2025
Period End
April 4, 2025
Security
EXEL
One revenue dollarkept$0.29
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed May 13, 2025. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported first-quarter 2025 total revenues of $555.4 milliona, up from $425.2 million a year earlier, driven by net product revenues of $513.3 million compared with $378.5 million.

CABOMETYX net product revenues were $510.9 millionb, and the filing attributes the increase primarily to a 25% increase in CABOMETYX units sold and a 9% increase in average net selling price. Net income was $159.6 million, or $0.55 per diluted share, versus $37.3 million, or $0.12 per share, in the prior-year quarter. The prior-year period included $32.8 million in restructuring expenses, which were absent in 2025.

Research and development expenses declined to $212.2 millionc from $227.7 million, while selling, general and administrative expenses rose to $137.2 million from $114.0 million. Cash flow from operations was $211.4 million, compared with $68.8 million a year earlier. The company ended the quarter with $1.65 billion in cash, cash equivalents and marketable securities, down from $1.75 billion at year-end 2024, after repurchasing $283.9 million of common stock in cash during the quarter.

Under two authorizations totaling $1.0 billiond, $494.5 million of stock has been repurchased to date, leaving about $505.5 million available through December 31, 2025. The company states it expects its current resources to fund operations for at least 12 months. The filing highlights ongoing patent litigation over CABOMETYX.

Multiple generic ANDA filers (MSN, Sun, Biocon) and Azurity's 505(b)(2) application have filed Paragraph IV certifications, and the company has sued each of them. In the MSN II case, the Delaware District Court ruled in October 2024 that the effective date of any FDA approval of MSN's ANDA would not be earlier than January 15, 2030, and MSN has appealed. The company also reported an FDA approval in March 2025 for CABOMETYX in previously treated advanced neuroendocrine tumors, and it stated that it expects net product revenues to increase for the remainder of 2025 partly because of that approval.

Key Highlights

  1. Total revenues of $555.4 million rose 31% from $425.2 million, with net product revenues up 36% to $513.3 million.
  2. Net income of $159.6 million ($0.55 diluted EPS) compared with $37.3 million ($0.12 per share) in Q1 2024.
  3. Income from operations was $186.9 million versus $29.5 million, and the prior-year quarter included $32.8 million in restructuring expenses.
  4. Operating cash flow was $211.4 million, up from $68.8 million, while cash, equivalents and marketable securities totaled $1.65 billion at March 31, 2025.
  5. Company repurchased $494.5 million of common stock under two programs since August 2024, with approximately $505.5 million remaining authorized through December 31, 2025.
  6. Multiple generic and 505(b)(2) challengers to CABOMETYX have filed Paragraph IV certifications, and the company has filed patent infringement suits against each, with MSN II's ruling setting an effective approval date no earlier than January 15, 2030.
  7. FDA approved CABOMETYX in March 2025 for previously treated advanced neuroendocrine tumors, and the company projects net product revenues may increase over the remainder of 2025.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2026, Exelixis kept $0.29.

  1. Revenue$555.4M100.0%
  2. Cost of revenue−$19.2M3.5%
  3. Gross profit$536.3M96.5%
  4. Operating costs−$349.4M62.9%
  5. Operating income$186.9M33.6%
  6. Interest, other & tax−$27.2M4.9%
  7. Net income$159.6M28.7%
Computed from 10-QQ1 FY2026filed May 13, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$555.45M$425.23M+30.6%
Cost of Revenue$19.17M$21.26M−9.8%
Gross Profit$536.27M$403.97M+32.8%
R&D Expenses$212.23M$227.69M−6.8%
SG&A Expenses$137.18M$113.98M+20.4%
Operating Expenses$368.59M$395.76M−6.9%
Operating Income$186.86M$29.46M+534.2%
Net Income$159.62M$37.32M+327.7%
EPS (Basic)$0.57$0.12+375.0%
EPS (Diluted)$0.55$0.12+358.3%
Shares Outstanding (Basic)278.80M300.76M−7.3%
Shares Outstanding (Diluted)288.18M305.53M−5.7%

Frequently Asked Questions

  1. What drove the increase in Exelixis's net product revenues this quarter?

    Net product revenues rose to $513.3 million from $378.5 million. The filing attributes the increase primarily to a 25% increase in the number of CABOMETYX units sold, reflecting continuing demand for CABOMETYX in combination with nivolumab as a first-line treatment for advanced RCC, and to a lesser extent a 9% increase in average net selling price.

  2. How much cash did Exelixis return to shareholders through buybacks, and how much authorization remains?

    The company repurchased 8.1 million shares in the quarter for $291.3 million in equity terms, and cash payments for repurchases totaled $283.9 million. Across both programs, 14.2 million shares have been repurchased for $494.5 million, leaving about $505.5 million available for repurchases before December 31, 2025.

  3. What are the main patent-related risks to CABOMETYX revenue?

    Several companies, including MSN, Sun, Biocon and Azurity, have filed applications seeking to market generic or alternative cabozantinib (S)-malate tablets, and each has been subject to Paragraph IV certifications challenged by Exelixis in Delaware. The filing states that approval and launch of any such generic could significantly decrease U.S. CABOMETYX revenues. In the MSN II case, the court ruled the earliest effective approval date would be January 15, 2030, and MSN has appealed to the Federal Circuit.

  4. Why did operating expenses decline year over year even as revenue grew?

    Total operating expenses fell to $368.6 million from $395.8 million. The prior-year quarter included $32.8 million in restructuring charges that did not recur. Research and development expenses decreased to $212.2 million from $227.7 million, mainly due to lower license and collaboration costs and lower clinical trial costs, partially offset by higher stock-based compensation and personnel expenses. Selling, general and administrative expenses rose to $137.2 million from $114.0 million.

  5. What is the company's outlook for its pipeline and near-term spending?

    The company says it expects clinical trial costs to increase for the remainder of 2025, driven by studies of zanzalintinib, XL309 and XB628, partially offset by lower cabozantinib and XB002 study costs. It anticipates initial clinical data readouts from STELLAR-002 in the first half of 2025, with STELLAR-303 preliminary results expected in the second half of 2025 depending on event rates.